文献速递核素与放射性配体治疗

晚期难治性脑膜瘤的肽受体放射性核素治疗:长期随访中的疗效与毒性

Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.
PubMed 文献 · J Nucl Med · 2024-09-03

该研究纳入42例标准治疗后影像学复发的脑膜瘤患者,接受90Y-DOTATOC或177Lu-DOTATATE治疗,中位随访63个月,疾病控制率为57%,中位无进展生存期16个月,中位总生存期36个月;仅1例因3级血小板毒性终止治疗。

要点

  • 42例复发脑膜瘤患者接受PRRT,疾病控制率为57%。
  • 中位随访63个月,中位无进展生存期16个月,中位总生存期36个月。
  • 仅1例因3级血小板毒性终止治疗,1例再治疗患者出现短暂2级中性粒细胞减少。

核心结论

  • PRRT在生长抑素受体2过表达的晚期脑膜瘤患者中具有活性且耐受良好,疾病控制率为57%。
  • PRRT可能作为潜在的再治疗选择。
  • 需要进一步研究,包括与其他治疗联合的研究。

研究设计与样本

  • 2009年10月至2021年10月,42例标准治疗后影像学复发的脑膜瘤患者接受90Y-DOTATOC(剂量1.1或5.5 GBq)或177Lu-DOTATATE(剂量3.7或5.5 GBq)治疗,平均4个周期。
  • 所有患者在诊断性68Ga-DOTATOC PET/CT或111In-奥曲肽扫描中均显示强烈摄取。

主要发现

  • 42例患者中,5例接受90Y-DOTATOC累积活度11.1 GBq,37例接受177Lu-DOTATATE累积活度22 GBq。
  • 疾病控制率为57%。
  • 中位随访63个月,中位无进展生存期16个月,中位总生存期36个月。
  • 6例患者接受177Lu-PRRT再治疗,中位给药活度13 GBq,平均5个周期;随访75.8个月,中位无进展生存期和总生存期分别为6.5个月和17个月。
  • 仅1例患者因3级血小板毒性终止治疗;1例再治疗患者记录到快速短暂的2级中性粒细胞减少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究,包括与其他治疗联合的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recurrence of meningiomas after surgery and radiotherapy deserves specific attention because of the lack of active third-line therapies. Somatostatin receptors are usually overexpressed on the cell membrane of meningiomas, and this has led the way to a radionuclide theranostic approach. Diagnoses with 68Ga-DOTA-octreotide and peptide receptor radionuclide therapy (PRRT) with 90Y/177Lu-DOTA-octreotide are currently possible options within experimental protocols or as compassionate use in small patient groups. Methods: From October 2009 to October 2021, 42 meningioma patients with radiologic recurrence after standard therapies were treated with 90Y-DOTATOC (dosage of 1.1 or 5.5 GBq) or with 177Lu-DOTATATE (dosage of 3.7 or 5.5 GBq) in a mean of 4 cycles. All patients showed intense uptake at diagnostic 68Ga-DOTATOC PET/CT or in an 111In-octreotide scan. Results: Of 42 patients treated, 5 patients received 90Y-DOTATOC with a cumulative activity of 11.1 GBq and 37 patients received 177Lu-DOTATATE with a cumulative activity of 22 GBq. The disease control rate was 57%. With a median follow-up of 63 mo, median progression-free survival was 16 mo, and median overall survival was 36 mo. Retreatment 177Lu-PRRT was performed in 6 patients with an administered median activity of 13 GBq in a mean of 5 cycles. With a 75.8-mo follow-up, median progression-free survival and overall survival were 6.5 and 17 mo, respectively. Only 1 patient discontinued the treatment because of grade 3 platelet toxicity. A rapidly transient grade 2 neutropenia was recorded in 1 retreated patient. Conclusion: PRRT in patients with advanced meningiomas overexpressing somatostatin receptor 2 was active and well tolerated, showing a 57% disease control rate. Furthermore, PRRT could represent a potential retreatment option. Further studies, also in combination with other treatments, are warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Severi S, Grassi I, Bongiovanni A, et al. Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up. J Nucl Med. 2024. PMID: 39142827. doi:10.2967/jnumed.123.266956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。